Beckman Coulter Features Prostate Health Index (phi) at 2016 AUA Annual Meeting

BREA, CALIF. — (May 6, 2016) — Beckman Coulter Diagnostics, a leader in prostate cancer testing, will demonstrate its dedication to advancing healthcare for patients and physicians at the 2016 American Urological Association (AUA) Annual Meeting in San Diego, CA, May 6-11, 2016.

The Beckman Coulter exhibition booth (#4241) will showcase the company’s Prostate Health Index (phi)*-a diagnostic blood test that can help a physician determine whether or not an elevated PSA score means there is a risk for prostate cancer and whether a biopsy is needed.

“More confidence before you biopsy” is the tagline for this year’s show. The high-level messaging focuses on the phi test:

• Indicated for initial and repeat biopsy patients
• Included in the NCCN Guidelines, Melbourne Consensus Statement and EAU Guidelines
• Increased confidence through FDA PMA approved test

The phi test is a simple blood test, a powerful combination of three tests in one. A patient’s phi score gives more accurate information about what an elevated PSA level might mean and the probability of finding prostate cancer on biopsy. Beckman Coulter’s phi test fills the diagnostic gap between PSA screening and a prostate biopsy.

The phi test is now more broadly available to physicians nationwide. It can be run in your laboratory or there are a number of regional reference laboratories also running the test around the country. To learn more information on where phi is available visit booth # 4241 at AUA or visit www.prostatehealthindex.org.

In addition to the exhibition booth, Beckman Coulter is hosting the following events at the AUA Annual Meeting:

Industry Clinical Update (ICU) Theater:
“Prostate Health Index: A Global Clinical Update”
Science and Technology Hall, Booth #2933
Saturday, May 7, 2016 | 11 a.m.-12 p.m. PT

Presented by:

Program chair: Dr. William Catalona

phi Poster Presentations:

Clinical utility of phi (Prostate Health Index) in men with tPSA >10 ng/ml. Results from a multicentric European study

Comparison of Prostate Health Index (phi) and multiparametric magnetic resonance imaging (MRI) in detection of clinically-significant prostate cancer

Diagnostic accuracy of Prostate Health Index for aggressive prostate cancer: An institutional validation study

Changes in Prostate Health Index (phi) over time

Management of common PSA dilemmas

Beyond PSA: Utilization of novel prostate cancer genomic biomarkers for the practicing urologist

Visitors to Beckman Coulter’s booth will have opportunities to learn from industry experts on how the company’s latest diagnostic prostate cancer innovation is enabling physicians with better knowledge and greater confidence in patient care.

 
About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes, offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, microbiology, automation and information systems. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.